$JAZZ

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy showed a statistically significant overall survival benefit over trastuzumab in the Phase 3 HERIZON-GEA-01 trial. The study involved 914 patients across 30+ countries. The FDA approved Ziihera for first-line treatment of HER2-positive gastroesophageal adenocarcinoma, providing a commercial pathway. However, the magnitude of the survival benefit and safety concerns remain key factors for adoption.

COZADD BRUCE C sold 6,000 shares of Jazz Pharmaceuticals plc (JAZZ) at $250.13 ($1.50M total) on 2026-09-01 under a Rule 10b5-1 trading plan.

Jazz Pharmaceuticals (JAZZ) shares fell 6.9% since its last earnings report. Q2 2026 adjusted EPS missed estimates at $5.71, but revenues rose 16% YoY to $1.21B, beating expectations. The company raised 2026 revenue guidance to $4.60-$4.75B. Xywav sales grew 13% YoY, while Xyrem sales declined 14% YoY. Oncology sales increased 32% YoY, driven by Zepzelca's 42% growth.

Jazz Pharmaceuticals announced that zanidatamab plus chemotherapy showed improved overall survival in HER2+ advanced GEA patients compared to trastuzumab, per HERIZON-GEA-01 trial results. The HR for OS improved with longer follow-up. The FDA approved zanidatamab in August 2026 for first-line treatment, supported by earlier trial data. Jazz plans to present updated data at a medical meeting and submit findings to global health authorities.

Jazz Pharmaceuticals (JAZZ) rose 2.5% after positive Phase 3 trial results. SAIC (SAIC) gained 5.5% on strong Q2 earnings. Herbalife (HLF) fell 13.2% following CEO's departure announcement. AGCO (AGCO) and Deere (DE) rose 4% and 3.1% respectively after Baird upgrades.

Iannone Robert (EVP, Global Head of R&D & CMO) sold 76,921 shares of Jazz Pharmaceuticals plc (JAZZ) at an average of $249.70 ($247.86–$252.76, $19.21M total) across 6 trades on 2026-08-27 under a Rule 10b5-1 trading plan.

Jazz Pharmaceuticals plc (JAZZ) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Exhibit 99.1 Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases DUBLIN, August 26, 2026 -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz Pharmaceuticals”) today announced that Jazz Inves

Jazz Pharmaceuticals (JAZZ) director Ted W. Love plans to sell 1,527 shares, valued at $373,413, on August 31, 2026, following restricted stock vesting on August 28, 2026, according to a Rule 144 notice.

Jazz Pharmaceuticals (JAZZ) shares rose 2.5% after positive Phase 3 trial results for Ziihera combined with chemotherapy in advanced gastroesophageal adenocarcinoma. The trial showed a statistically significant overall survival benefit, reinforcing the drug's potential. The stock closed at $250.79, up 2.6% from the previous close. JAZZ is up 44.8% year-to-date and near its 52-week high of $261.62.

Jazz Pharmaceuticals (JAZZ) reported that Ziihera, combined with chemotherapy, showed statistically significant overall survival benefits in a Phase 3 trial for HER2+ advanced gastroesophageal adenocarcinoma (GEA). The results support Ziihera as a new standard of care, following its recent FDA approval. The company plans to present the data at a major medical meeting in Q4 2026.